Development and validation of a high throughput LC–MS/MS method for simultaneous quantitation of pioglitazone and telmisartan in rat plasma and its application to a pharmacokinetic study
Open Access
- 1 December 2017
- journal article
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 7 (6) , 381-387
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infectionParasites & Vectors, 2013
- Does the PPAR-γ-activating property of telmisartan provide a benefit in clinical practice?Hypertension Research, 2012
- Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino ratsRegulatory Toxicology and Pharmacology, 2012
- Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytesJournal Of Hypertension, 2012
- PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ ProtectionThe Journal of Clinical Hypertension, 2011
- Development and validation of an LC‐ESI‐MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic applicationBiomedical Chromatography, 2010
- Telmisartan Effects on Insulin Resistance in Obese or Overweight Adults Without Diabetes or HypertensionThe Journal of Clinical Hypertension, 2010
- PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial FibrosisJournal of Korean Medical Science, 2010
- Interference with PPARγ Function in Smooth Muscle Causes Vascular Dysfunction and HypertensionCell Metabolism, 2008